A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

Completed · Phase 2 · Has a placebo group

Conditions studied: Overweight or Obesity, CKD, Type 2 Diabetes

In brief

The main purpose of this study is to investigate the effect of retatrutide on renal function in participants with overweight or obesity and chronic kidney disease (CKD), with or without Type 2 Diabetes (T2D). The study will last around 31 weeks.

Key facts

Study ID

NCT05936151

Run by

Eli Lilly and Company

People needed

146

Starts

2023-07-20

Expected to finish

2025-10-21

Last updated by the study team

2025-11-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Have a body mass index (BMI) ≥27 kilogram/square meter (kg/m²)
• Have either
• no T2D with an HbA1c < 6.5% or
• have T2D with an HbA1c ≤ 9.5% and treated with diet and exercise only or with stable doses of up to 3 oral antihyperglycemic medications, with or without basal insulin for at least 90 days before screening.
• Have been diagnosed with chronic kidney disease (CKD).

You may not qualify if…

• Have a self-reported change in body weight >5 kilogram (kg) (11 pounds) within 90 days before screening.
• Have used in 90 days before the screening any of the following antihyperglycemic class: Dipeptidyl Peptidase IV (DPP4) inhibitors, amylin analogs, glucagon-like peptide-RA (GLP-RA), gastric inhibitory polypeptide (GIP)/GIP-1 RA, and short acting or rapid acting insulins or U500 Insulin
• Have a prior or planned surgical treatment for obesity
• Have Type 1 Diabetes (T1D)
• Have acute or chronic hepatitis
• Have a history of malignant disease within 5 years before screening.

Where it is running

• The Institute for Liver Health II dba Arizona Clinical Trials - Mesa — Chandler, Arizona, United States
• Care Access - 801 South Power Road, Mesa — Mesa, Arizona, United States
• Headlands Research - Scottsdale — Scottsdale, Arizona, United States
• Medical Advancement Centers of Arizona — Tempe, Arizona, United States
• Hope Clinical Research, Inc. — Canoga Park, California, United States
• Catalina Research Institute, LLC — Montclair, California, United States
• Peninsula Research Associates — Rolling Hills Estates, California, United States
• University of Colorado Anschutz Medical Campus — Aurora, Colorado, United States
• Teradan Clinical Trials, LLC — Brandon, Florida, United States
• Suncoast Clinical Research, Inc. — New Port Richey, Florida, United States
• Great Lakes Clinical Trials - Ravenswood — Chicago, Illinois, United States
• Indiana University Health University Hospital — Indianapolis, Indiana, United States
• Prime Health and Wellness/SKYCRNG — Fayette, Mississippi, United States
• Palm Research Center Tenaya — Las Vegas, Nevada, United States
• NYU Langone Hospital - Long Island — Mineola, New York, United States
• Cleveland Clinic — Cleveland, Ohio, United States
• Victorium Clinical Research - Houston — Houston, Texas, United States
• Endocrine Ips, Pllc — Houston, Texas, United States
• Tranquility Research — Webster, Texas, United States
• Centricity Research Brampton Endocrinology — Brampton, Ontario, Canada
• Circulate Cardiac & Vascular Centre — Burlington, Ontario, Canada
• North York Diagnostic and Cardiac Centre — North York, Ontario, Canada
• Stouffville Medical Research Institute Inc. — Stouffville, Ontario, Canada
• Dr. Anil K. Gupta Medicine Professional Corporation — Toronto, Ontario, Canada
• Fadia El Boreky Medicine — Waterloo, Ontario, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.